Although KRAS mutation has been studied for the predictive value of tumor response to anti-EGFR treatment and also has been confirmed to be the highly predictive of resistance to anti-EGFR treatment [11-18], the prognostic value of KRAS mutation in synchronous and metachronous mCRC remains controversial [18-28]. Here, EGFR is linked to neoplasm.